Wegovy Launches Direct-to-Consumer Weight Loss Program

Novo Nordisk on Tuesday, March 31, rolled out a multi-month subscription option for its Wegovy obesity treatments, aiming to give cash-paying patients a lower and more predictable monthly bill. The company said the program is built around fixed monthly pricing that stays consistent even when a patient’s prescribed dose changes over time.

Eligible patients can select three-, six-, or 12-month plans. Novo Nordisk said the subscriptions cover Wegovy injections or the two highest doses of its newly launched oral formulation, offering an alternative for patients who are paying without insurance coverage and want cost certainty across treatment adjustments.

The company said longer commitments come with reduced monthly pricing compared with purchasing doses month to month. Based on its comparisons to monthly dose purchases, Novo Nordisk said the structure can amount to annual savings of up to $1,200 for the injection and up to $600 for the pill. As an illustration of the pricing, the company listed a 12-month injection subscription at $249 per month, and a 12-month pill subscription also at $249 per month.

Access to the subscription is being distributed through telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers. Novo Nordisk positioned this approach as a way to place the offer inside digital care channels that many patients already use for evaluation, prescribing, and follow-up, while reducing uncertainty for people paying out of pocket and supporting continuity of treatment.

Novo Nordisk also tied the initiative to adherence challenges it said have long affected GLP-1 therapies in obesity care. The company cited historical patterns indicating that about 65% of patients with obesity discontinue treatment within a year, and framed the subscription’s flat monthly price across dose changes—along with lower monthly costs for longer enrollment—as a tool intended to help patients stay on therapy longer.

The launch arrives as competition remains intense in the U.S. branded GLP-1 market. Novo Nordisk is cited as holding about 39% of that market, while Eli Lilly is cited at approximately 60%, according to the figures referenced in the source material. Novo Nordisk’s move also comes as Eli Lilly is expected to introduce its own oral GLP-1 product later this year, adding to rivalry that already includes injectable options.

Key unknowns remain, including how many cash-paying patients will qualify and how quickly enrollment could scale through the listed telehealth partners. It is also unclear how the subscription will interact with broader pricing dynamics across GLP-1 therapies, since the offer is aimed specifically at patients paying without insurance. Even so, the announcement signals a push by Novo Nordisk to make patient costs more predictable while reinforcing its position in a fast-moving category.